Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin.
暂无分享,去创建一个
S. Larson | M. Fleisher | R. Tuttle | A. Shaha | R. Robbins | M. Sonenberg | R. Sharaf | H. Robbins
[1] S. Larson,et al. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[2] S. Larson,et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[3] J. Humm,et al. Thyroid cancer dosimetry using clearance fitting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] R. Weigel,et al. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. , 1999 .
[5] P. Perros. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. , 1999, Journal of endocrinological investigation.
[6] G. Mariani,et al. Mapping sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue-dye, and intraoperative gamma-probe. , 2000, Cancer biotherapy & radiopharmaceuticals.
[7] R. Tsang,et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma , 1998, Cancer.
[8] E. Mazzaferri. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. , 1997, Thyroid : official journal of the American Thyroid Association.
[9] L. Wartofsky. Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma , 1998 .
[10] M. Burge,et al. Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin. , 1999, Thyroid : official journal of the American Thyroid Association.
[11] H. Macapinlac,et al. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. , 1998, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[12] D. Roos,et al. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique. , 1999, International journal of radiation oncology, biology, physics.
[13] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[14] B. Weintraub,et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.
[15] L. Braverman,et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). , 1994, The Journal of clinical endocrinology and metabolism.
[16] B. de Keizer,et al. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy , 2000, Nuclear medicine communications.
[17] C. Bal,et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.
[18] E. Molinari,et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. , 2000, Cancer biotherapy & radiopharmaceuticals.
[19] M. Sonenberg,et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.
[20] B. Ferrell,et al. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. , 1997, Thyroid : official journal of the American Thyroid Association.
[21] J. Shah,et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.
[22] R. Leeper. The Effect of 131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma , 1973 .
[23] G. Beckett,et al. Use of recombinant thyrotropin , 2002, The Lancet.
[24] J. Garber,et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.